ZLDPF Stock - Zealand Pharma A/S
Unlock GoAI Insights for ZLDPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $62.69M | $342.79M | $103.99M | $292.57M | $353.31M |
| Gross Profit | $54.82M | $323.61M | $73.28M | $173.75M | $262.75M |
| Gross Margin | 87.4% | 94.4% | 70.5% | 59.4% | 74.4% |
| Operating Income | $-1,272,207,000 | $-572,238,000 | $-816,599,000 | $-1,050,197,000 | $-828,756,000 |
| Net Income | $-1,078,828,000 | $-703,739,000 | $-965,610,000 | $-1,018,149,000 | $-846,729,000 |
| Net Margin | -1720.9% | -205.3% | -928.6% | -348.0% | -239.7% |
| EPS | $-16.24 | $-12.44 | $-20.90 | $-23.75 | $-22.07 |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 8th 2024 | JP Morgan | Initiation | Overweight | - |
| May 21st 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| March 7th 2024 | BTIG Research | Initiation | Buy | - |
Earnings History & Surprises
ZLDPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-1.34 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-1.11 | $-0.90 | +18.9% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $17.22 | $16.06 | -6.7% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.77 | $-0.67 | +13.0% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-0.74 | $-0.59 | +20.8% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.62 | $-0.56 | +9.7% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-0.61 | $-0.67 | -9.8% | ✗ MISS |
Q2 2024 | May 16, 2024 | $-0.60 | $-0.54 | +9.4% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.58 | $-0.66 | -13.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.53 | $0.18 | +134.0% | ✓ BEAT |
Q3 2023 | Aug 17, 2023 | $-0.52 | $-0.80 | -53.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.54 | $-0.54 | +0.4% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | — | $-0.93 | — | — |
Q4 2022 | Nov 10, 2022 | $-0.68 | $-0.45 | +33.8% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.11 | $-1.40 | -26.4% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.99 | $-0.63 | +36.1% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.99 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-0.73 | — | — |
Q3 2021 | Aug 12, 2021 | — | $-1.11 | — | — |
Frequently Asked Questions about ZLDPF
What is ZLDPF's current stock price?
What is the analyst price target for ZLDPF?
What sector is Zealand Pharma A/S in?
What is ZLDPF's market cap?
Does ZLDPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZLDPF for comparison